SIM-0609

N/A

Report date: 2025/09/05 16:39:43

Base Information

Drug NameSIM-0609
Drug Alias NameSIM0609SIM-0609
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > CPT116 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-Cadherin-17DNA topoisomerase I inhibitors
TargetsCadherin-17DNA topoisomerase I
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisGastrointestinal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Xianwei Pharmaceutical Technology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Xianwei Pharmaceutical Technology Co LtdSimcere Pharmaceutical Group LtdJiangsu Simcere Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasm MetastasisGastrointestinal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A